Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKα/β Kinases and Regulates NF-κB /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate

References

• Mrowietz U, Asadullah K. Dimethyl fumarate for psoriasis: more than a dietary curiosity. Trend Mol Med. 2005;11(1):43–48. doi:10.1016/j.molmed.2004.11.003
   PubMed Web of Science ®Google Scholar
• Smith TE. Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis. Zh Neurol Psikhiatr Im S S Korsakova. 2017;117(11):140–145. doi:10.17116/jnevro2017117111140-145
   Google Scholar
• Blair HA. Dimethyl fumarate: a review in moderate to severe plaque psoriasis. Drugs. 2018;78(1):123–130. doi:10.1007/s40265-017-0854-629236231
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.24655295
   PubMed Web of Science ®Google Scholar
• Peng H, Guerau-de-Arello M, Metha VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):2817–2826.
   Web of Science ®Google Scholar
• Rescigno M, Martino M, Satherland C, et al. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med. 1998;188(11):2175–2180.9841930
   PubMed Web of Science ®Google Scholar
• McGuire VA, Ruiz-Zorrilla Diez T, Emmerich CH, et al. Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. Sci Rep. 2016;6:31159.27498693
   PubMed Web of Science ®Google Scholar
• Arthur JC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679–692.23954936
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schulterwolter T, Ockenfels G, et al. The anti-psoriatic agent dimethyl fumarate immune-modulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139(3):390–395.9767281
   PubMed Web of Science ®Google Scholar
• Tahvili S, Zandieh B, Amirghofran Z. The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. Int J Dermatol. 2015;54(7):e254–60. doi:10.1111/ijd.2015.54.issue-726108267
   PubMed Web of Science ®Google Scholar
• Bech R, Otkjær K, Birkelund S, et al. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Exp Dermatol. 2014;23(5):349–352. doi:10.1111/exd.2014.23.issue-524628979
   PubMed Web of Science ®Google Scholar
• Gesser B, Johansen C, Rasmussen MK, et al. Dimethyl fumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol. 2007;127(9):2129–2137. doi:10.1038/sj.jid.570085917495961
   PubMed Web of Science ®Google Scholar
• Gerhardt S, König VM, Doll M, et al. Dimethyl fumarate protects against TNF-α induced secretion of inflammatory cytokines in human endothelial cells. J Inflamm. 2015;12:49.
   Google Scholar
• Walbrecht K, Drick N, Hund AC, Schön MP. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp Dermatol. 2011;20(12):980–985. doi:10.1111/j.1600-0625.2011.01376.x21995308
   PubMed Web of Science ®Google Scholar
• Rubant SA, Ludwig RJ, Diehl S, et al. Dimethylfumarate reduces leukocytes rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol. 2008;128(2):326–331. doi:10.1038/sj.jid.570099617671516
   PubMed Web of Science ®Google Scholar
• Johansen C, Kragballe K, Westergaard M, et al. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol. 2005;152(1):37–42. doi:10.1111/bjd.2005.152.issue-115656798
   PubMed Web of Science ®Google Scholar
• Funding AT, Johansen C, Kragballe K, et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol. 2006;126(8):1784–1791. doi:10.1038/sj.jid.570025216543895
   PubMed Web of Science ®Google Scholar
• Vermeulen L, De Wilde G, Van Damme P, et al. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003;22(6):1313–1324. doi:10.1093/emboj/cdg13912628924
   PubMed Web of Science ®Google Scholar
• Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol. 2004;5(5):393–401. doi:10.1038/nrm1368
   Web of Science ®Google Scholar
• Rasmussen MK, Nielsen J, Kjellerup RB, et al. Protein phosphatase 2Cδ/Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin. J Inflamm Res. 2017;10:169–180. doi:10.2147/JIR.S15286929290690
   PubMed Web of Science ®Google Scholar
• Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441(2):553–569. doi:10.1042/BJ2011028922187936
   PubMed Web of Science ®Google Scholar
• Schouten GJ, Vertegaal ACO, Whiteside ST, et al. IκBα is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J. 1997;16(11):3133–3144. doi:10.1093/emboj/16.11.31339214631
   PubMed Web of Science ®Google Scholar
• Peng C, Cho YY, Zhu F, et al. RSK2 mediates NF-κB activity through the phosphorylation of IκBα in the TNF-R1 pathway. FASEB J. 2010;24(9):3490–3499. doi:10.1096/fj.09-15129020385620
   PubMed Web of Science ®Google Scholar
• Peng C, Cho YY, Zhu F, et al. Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 Kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J Biol Chem. 2011;286(9):6946–6954. doi:10.1074/jbc.M110.17233821183680
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Meinhardt A, Steinhoff A, et al. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin diseases. Br J Dermatol. 1999;141:1061–1066. doi:10.1046/j.1365-2133.1999.03206.x10606853
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nishihira J, Mizue Y, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol. 2001;116:989–990. doi:10.1046/j.0022-202x.2001.01366.x11407993
   PubMed Web of Science ®Google Scholar
• Gesser B, Rasmussen MK, Raaby L, et al. Dimethyl fumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (c63) and p-p53 (S15) expression. Inflamm Res. 2011;60(7):643–653. doi:10.1007/s00011-011-0316-721340650
   PubMed Web of Science ®Google Scholar
• Anderson KS, Petersson S, Wong J, et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010;163(5):1085–1089. doi:10.1111/j.1365-2133.2010.09990.x20716221
   PubMed Web of Science ®Google Scholar
• Perkins ND. Post–translational modifications regulate the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006;25(51):6717–6730. doi:10.1038/sj.onc.120993717072324
   PubMed Web of Science ®Google Scholar
• Lee FS, Peters RT, Dang LC, Maniatis T. MEKK1 activates both IκB kinase α and IκB kinase β. Proc Natl Acad Sci. 1998;95(16):9319–9324. doi:10.1073/pnas.95.16.93199689078
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signaling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49–62. doi:10.1038/nrm208317183360
   PubMed Web of Science ®Google Scholar
• Sakurai H, Chiba H, Miyoshi H, et al. IκB kinases phosphorylate NF-κB subunit on serine 536 in the transactivation domain. J Biol Chem. 1999;274(43):3053–3056. doi:10.1074/jbc.274.43.30353
   Web of Science ®Google Scholar
• Lawrence T, Bebien M, Liu G, Nizet V, Karin M. IKKalpha limits macrophage NF-κB activation and contributes to the resolution of Inflammation. Nature. 2005;434(7037):1138–1143. doi:10.1038/nature0349115858576
   PubMed Web of Science ®Google Scholar
• Sasaki CY, Barberi TJ, Ghosh P, Longo DJ. Phosphorylation of RelA/p65 on Serine 536 defines an IκBα-independent NF-κB pathway. J Biol Chem. 2005;280(41):34538–34547. doi:10.1074/jbc.M50494320016105840
   PubMed Web of Science ®Google Scholar
• Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-κB controls expression of inhibitor IκBα: evidence for an inducible autoregulatory pathway. Science. 1993;259(5103):1912–1915. doi:10.1126/science.80960918096091
   PubMed Web of Science ®Google Scholar
• Nicolay JP, Müller-Decke K, Schroeder A, et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastases in CTCL by targeting NF-κB activity. Blood. 2016;128(6):805–815. doi:10.1182/blood-2016-01-69411727268084
   PubMed Web of Science ®Google Scholar
• Bunell TM, Burbach BJ, Shimizu Y, Ervasti JM. β-Actin specifically controls cell growth, migration and the G-actin pool. Mol Biol Cell. 2011;22(21):4047–5835.21900491
   PubMed Web of Science ®Google Scholar
• Rhee I, Zhong MC, Reizis B, et al. Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells. Mol Cell Biol. 2014;34(5):888–899.24366546
   PubMed Web of Science ®Google Scholar
• Krishnan N, Bencze G, Cohen P, Tonks NK. The anti-inflammatory compound BAY 11-7082 is a potent inhibitor of protein tyrosine phosphatases. FEBS J. 2013;280(12):2830–2841.23578302
   PubMed Web of Science ®Google Scholar
• Andersen JL, Gesser B, Funder ED, et al. Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases. Nat Commun. 2018;9(1):4344.30341347
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Morrision PJ, Suhrkamp I, Kumanova M, Clement B. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Pharmacol Sci. 2018;39(1):1–12.29183628
   PubMed Web of Science ®Google Scholar
• Walker F, Adamczyk A, Kellerer C, et al. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. Br J Dermatol. 2014;171(5):1197–1205.24813676
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of Apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383–1388.14675187
   PubMed Web of Science ®Google Scholar
• Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signaling. Nat Rev Mol Cell Biol. 2008;10:747–758.
   Web of Science ®Google Scholar
• Bohuslav J, Chen LF, Kwon H, et al. P53 induces NF-κB kinase independent mechanism involving RSK1 phosphorylation of p65. J Biol Chem. 2004;279(25):26115–26125.15073170
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock A. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2016;64:66–73.
   Web of Science ®Google Scholar
• Chew J, Biswas S, Shreeram S, et al. WiP1 phosphatase is negative regulator of NF-κB signaling. Nat Cell Biol. 2009;11(5):659–666.19377466
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Comm. 2005;331(3):851–858.15865941
   PubMed Web of Science ®Google Scholar